Uploaded September 2026 | Updated November 2026, 4 days ago
Limb Girdle Muscular Dystrophy (LGMD) is a rare and progressive genetic disorder with over 30 subtypes. LGMD can impact not only mobility but also the heart, lungs, and muscles that support breathing.
One subtype, LGMD2I/R9, is an FKRP-related form of the disease that affects an estimated 7,000 individuals in the United States and Europe. There is currently no cure or disease-modifying treatment for any type of LGMD, so care focuses on managing symptoms and maintaining function.
We’ll go beyond the diagnosis to explore life with FKRP-related LGMD and the remarkable community helping patients face the future with strength and hope.
Learn more: knowlgmd.com
Visit: thebalancingact.com
Like: facebook.com/TheBalancingActFans
Follow: twitter.com/BalancingActTV
#TheBalancingAct #BalancingAct
Limb Girdle Muscular Dystrophy (LGMD) is a rare and progressive genetic disorder with over 30 subtypes. LGMD can impact not only mobility but also the heart, lungs, and muscles that support breathing.
One subtype, LGMD2I/R9, is an FKRP-related form of the disease that affects an estimated 7,000 individuals in the United States and Europe. There is currently no cure or disease-modifying treatment for any type of LGMD, so care focuses on managing symptoms and maintaining function.
We’ll go beyond the diagnosis to explore life with FKRP-related LGMD and the remarkable community helping patients face the future with strength and hope.
Learn more: knowlgmd.com
Visit: thebalancingact.com
Like: facebook.com/TheBalancingActFans
Follow: twitter.com/BalancingActTV
#TheBalancingAct #BalancingAct




![Behind the Mystery of Paroxysmal Nocturnal Hemoglobinuria (PNH)
INDICATION
For the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
SELECT IMPORTANT SAFETY INFORMATION
What is the most important information I should know about ULTOMIRIS® (ravulizumab-cwvz)?
ULTOMIRIS is a medicine that affects your immune system and may lower the ability of your immune system to fight infections.
• ULTOMIRIS increases your chance of getting serious meningococcal infections that may quickly become life-threatening or cause death if not recognized and treated early.
1. You must complete or update meningococcal vaccine(s) at least 2 weeks before your first dose of ULTOMIRIS.
2. If you have not completed your meningococcal vaccines and ULTOMIRIS must be started right away, you should receive the required vaccine(s) as soon as possible.
3. If you have not been vaccinated and ULTOMIRIS must be started right away, you should also receive antibiotics for as long as your healthcare provider tells you.
4. If you had a meningococcal vaccine in the past, you might need additional vaccines before starting ULTOMIRIS. Your healthcare provider will decide if you need additional meningococcal vaccines.
5. Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: fever, fever with high heart rate, headache and fever, confusion, muscle aches with flu-like symptoms, fever and a rash, headache with nausea or vomiting, headache with a stiff neck or stiff back, or eyes sensitive to light.
Please see additional Important Safety Information in the video above and on https://ultomiris.com/pnh, the full Prescribing Information [https://bit.ly/4jYvAL3] and Medication Guide [https://bit.ly/4jpL1fe] for ULTOMIRIS, including Boxed WARNING regarding serious meningococcal infections.
BACTTV ALEAND 000005
Visit: http://www.thebalancingact.com
Like: https://www.facebook.com/TheBalancingActFans
Follow: https://twitter.com/BalancingActTV
#TheBalancingAct #BalancingAct Behind the Mystery of Paroxysmal Nocturnal Hemoglobinuria (PNH)](https://i.ytimg.com/vi/s3S_VgfVLw0/mqdefault.jpg)





